{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:35:56Z","timestamp":1785321356676,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370205"],"award-info":[{"award-number":["82370205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Social Development Project of Jiangsu Science and Technology Plan","award":["BE2022810"],"award-info":[{"award-number":["BE2022810"]}]},{"name":"Key Program of Taizhou School of Clinical Medicine of Nanjing Medical University","award":["TZKY20220310"],"award-info":[{"award-number":["TZKY20220310"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-024-03941-8","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T20:24:51Z","timestamp":1727468691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mesenchymal stem cell infusion for enhancing hematopoietic recovery and addressing cytopenias in CAR-T cell therapy"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-4955","authenticated-orcid":false,"given":"Yuan","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuxing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6497-1194","authenticated-orcid":false,"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"issue":"1","key":"3941_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","volume":"13","author":"R Huang","year":"2020","unstructured":"Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, Gao L, Wen Q, Zhong JF, Zhang C, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3941_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","volume":"21","author":"J Lu","year":"2022","unstructured":"Lu J, Jiang G. The journey of CAR-T therapy in hematological malignancies. Mol Cancer. 2022;21(1):194.","journal-title":"Mol Cancer"},{"issue":"18","key":"3941_CR3","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2217\/imt-2020-0181","volume":"12","author":"N El-Khazragy","year":"2020","unstructured":"El-Khazragy N, Ghozy S, Emad P, Mourad M, Razza D, Farouk YK, Mohamed NA, Ahmed MK, Youssef T, Bahnasawy YM, et al. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies. Immunotherapy. 2020;12(18):1341\u201357.","journal-title":"Immunotherapy"},{"issue":"2","key":"3941_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11684-021-0843-8","volume":"16","author":"L Fan","year":"2022","unstructured":"Fan L, Wang L, Cao L, Zhu H, Xu W, Li J. Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients. Front Med. 2022;16(2):285\u201394.","journal-title":"Front Med"},{"issue":"19","key":"3941_CR5","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, Xu J, Zhuang Y, Zhang W, Weng XQ, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019;116(19):9543\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3941_CR6","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1080\/07853890.2022.2136748","volume":"54","author":"Y Xia","year":"2022","unstructured":"Xia Y, Zhang J, Li J, Zhang L, Li J, Fan L, Chen L. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors. Ann Med. 2022;54(1):2951\u201365.","journal-title":"Ann Med"},{"issue":"4","key":"3941_CR7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ajh.26113","volume":"96","author":"SJ Nagle","year":"2021","unstructured":"Nagle SJ, Murphree C, Raess PW, Schachter L, Chen A, Hayes-Lattin B, Nemecek E, Maziarz RT. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. Am J Hematol. 2021;96(4):455\u201361.","journal-title":"Am J Hematol"},{"issue":"10","key":"3941_CR8","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, Shimoni A, Nagler A, Toren A, Jacoby E. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transpl. 2019;54(10):1643\u201350.","journal-title":"Bone Marrow Transpl"},{"key":"3941_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"key":"3941_CR10","doi-asserted-by":"publisher","first-page":"8901","DOI":"10.2147\/CMAR.S321202","volume":"13","author":"A Schaefer","year":"2021","unstructured":"Schaefer A, Huang Y, Kittai A, Maakaron JE, Saygin C, Brammer J, Penza S, Saad A, Jaglowski SM, William BM. Cytopenias after CD19 chimeric Antigen receptor T-Cells (CAR-T) therapy for diffuse large B-Cell lymphomas or transformed follicular lymphoma: a single Institution experience. Cancer Manag Res. 2021;13:8901\u20136.","journal-title":"Cancer Manag Res"},{"issue":"4","key":"3941_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/cells12040531","volume":"12","author":"B Reinhardt","year":"2023","unstructured":"Reinhardt B, Lee P, Sasine JP. Chimeric Antigen receptor T-Cell therapy and Hematopoiesis. Cells. 2023;12(4):531.","journal-title":"Cells"},{"issue":"5","key":"3941_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in Children and Young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"3941_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3941_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, Riddell SR, Maloney DG, Boeckh M, Turtle CJ. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018;131(1):121\u201330.","journal-title":"Blood"},{"issue":"1","key":"3941_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, Sorror ML, Turtle CJ, Maloney DG, Bar M. Late events after treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. Biol Blood Marrow Transpl. 2020;26(1):26\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"20","key":"3941_CR16","first-page":"2460","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141(20):2460\u20139.","journal-title":"Blood"},{"key":"3941_CR17","doi-asserted-by":"crossref","unstructured":"Fitzsimmons REB, Mazurek MS, Soos A, Simmons CA. Mesenchymal Stromal\/Stem Cells in Regenerative Medicine and Tissue Engineering. Stem Cells Int 2018, 2018:8031718.","DOI":"10.1155\/2018\/8031718"},{"issue":"3","key":"3941_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s12015-011-9228-8","volume":"7","author":"C Pontikoglou","year":"2011","unstructured":"Pontikoglou C, Deschaseaux F, Sensebe L, Papadaki HA. Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation. Stem cell Reviews Rep. 2011;7(3):569\u201389.","journal-title":"Stem cell Reviews Rep"},{"issue":"3","key":"3941_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.exphem.2006.10.015","volume":"35","author":"N Li","year":"2007","unstructured":"Li N, Feugier P, Serrurrier B, Latger-Cannard V, Lesesve JF, Stoltz JF, Eljaafari A. Human mesenchymal stem cells improve ex vivo expansion of adult human CD34\u2009+\u2009peripheral blood progenitor cells and decrease their allostimulatory capacity. Exp Hematol. 2007;35(3):507\u201315.","journal-title":"Exp Hematol"},{"issue":"7","key":"3941_CR20","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1084\/jem.20122252","volume":"210","author":"S Pinho","year":"2013","unstructured":"Pinho S, Lacombe J, Hanoun M, Mizoguchi T, Bruns I, Kunisaki Y, Frenette PS. PDGFRalpha and CD51 mark human nestin\u2009+\u2009sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. J Exp Med. 2013;210(7):1351\u201367.","journal-title":"J Exp Med"},{"issue":"2","key":"3941_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.imlet.2015.06.013","volume":"168","author":"ME Bernardo","year":"2015","unstructured":"Bernardo ME, Fibbe WE. Mesenchymal stromal cells and hematopoietic stem cell transplantation. Immunol Lett. 2015;168(2):215\u201321.","journal-title":"Immunol Lett"},{"issue":"4","key":"3941_CR22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3727\/096368912X655217","volume":"22","author":"KH Wu","year":"2013","unstructured":"Wu KH, Wu HP, Chan CK, Hwang SM, Peng CT, Chao YH. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: from bench to bedsides. Cell Transpl. 2013;22(4):723\u20139.","journal-title":"Cell Transpl"},{"issue":"1","key":"3941_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jot.2014.07.005","volume":"3","author":"S Huang","year":"2015","unstructured":"Huang S, Xu L, Sun Y, Wu T, Wang K, Li G. An improved protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. J Orthop Translat. 2015;3(1):26\u201333.","journal-title":"J Orthop Translat"},{"issue":"23","key":"3941_CR24","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1182\/blood.2020007876","volume":"137","author":"P Sommerkamp","year":"2021","unstructured":"Sommerkamp P, Romero-Mulero MC, Narr A, Ladel L, Hustin L, Schonberger K, Renders S, Altamura S, Zeisberger P, Jacklein K, et al. Mouse multipotent progenitor 5 cells are located at the interphase between hematopoietic stem and progenitor cells. Blood. 2021;137(23):3218\u201324.","journal-title":"Blood"},{"issue":"13","key":"3941_CR25","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.devcel.2021.05.018","volume":"56","author":"S Comazzetto","year":"2021","unstructured":"Comazzetto S, Shen B, Morrison SJ. Niches that regulate stem cells and hematopoiesis in adult bone marrow. Dev Cell. 2021;56(13):1848\u201360.","journal-title":"Dev Cell"},{"key":"3941_CR26","doi-asserted-by":"publisher","first-page":"215920","DOI":"10.1016\/j.canlet.2022.215920","volume":"550","author":"X Si","year":"2022","unstructured":"Si X, Gu T, Liu L, Huang Y, Han Y, Qian P, Huang H. Hematologic cytopenia post CAR T cell therapy: etiology, potential mechanisms and perspective. Cancer Lett. 2022;550:215920.","journal-title":"Cancer Lett"},{"issue":"5","key":"3941_CR27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Sauter CS, Shah NN, Abou-El-Enein M. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19(5):342\u201355.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"3941_CR28","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3324\/haematol.2019.238634","volume":"106","author":"JM Logue","year":"2021","unstructured":"Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021;106(4):978\u201386.","journal-title":"Haematologica"},{"issue":"7","key":"3941_CR29","doi-asserted-by":"publisher","first-page":"E249","DOI":"10.1002\/ajh.26551","volume":"97","author":"N Tabbara","year":"2022","unstructured":"Tabbara N, Sharp J, Gaut D, Pham TTD, Tang K, Oliai C, Sim MS, Schiller G, Young P, Sasine JP. Diminished durability of chimeric antigen receptor T-cell efficacy with severe or prolonged postinfusion cytopenias. Am J Hematol. 2022;97(7):E249\u201355.","journal-title":"Am J Hematol"},{"issue":"7","key":"3941_CR30","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/stem.3016","volume":"37","author":"A Andrzejewska","year":"2019","unstructured":"Andrzejewska A, Lukomska B, Janowski M. Concise Review: mesenchymal stem cells: from roots to Boost. Stem Cells. 2019;37(7):855\u201364.","journal-title":"Stem Cells"},{"issue":"6","key":"3941_CR31","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.immuni.2006.10.016","volume":"25","author":"T Sugiyama","year":"2006","unstructured":"Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25(6):977\u201388.","journal-title":"Immunity"},{"key":"3941_CR32","doi-asserted-by":"publisher","first-page":"600127","DOI":"10.3389\/fimmu.2020.600127","volume":"11","author":"R Miao","year":"2020","unstructured":"Miao R, Lim VY, Kothapalli N, Ma Y, Fossati J, Zehentmeier S, Sun R, Pereira JP. Hematopoietic stem cell niches and signals Controlling Immune Cell Development and maintenance of immunological memory. Front Immunol. 2020;11:600127.","journal-title":"Front Immunol"},{"issue":"2","key":"3941_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1365-2141.2009.07742.x","volume":"146","author":"M Mutschler","year":"2009","unstructured":"Mutschler M, Magin AS, Buerge M, Roelz R, Schanne DH, Will B, Pilz IH, Migliaccio AR, Pahl HL. NF-E2 overexpression delays erythroid maturation and increases erythrocyte production. Br J Haematol. 2009;146(2):203\u201317.","journal-title":"Br J Haematol"},{"issue":"1","key":"3941_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.exphem.2007.08.015","volume":"36","author":"EL Fock","year":"2008","unstructured":"Fock EL, Yan F, Pan S, Chong BH. NF-E2-mediated enhancement of megakaryocytic differentiation and platelet production in vitro and in vivo. Exp Hematol. 2008;36(1):78\u201392.","journal-title":"Exp Hematol"},{"issue":"9","key":"3941_CR35","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1182\/blood.V94.9.3037","volume":"94","author":"J Levin","year":"1999","unstructured":"Levin J, Peng JP, Baker GR, Villeval JL, Lecine P, Burstein SA, Shivdasani RA. Pathophysiology of thrombocytopenia and anemia in mice lacking transcription factor NF-E2. Blood. 1999;94(9):3037\u201347.","journal-title":"Blood"},{"issue":"5","key":"3941_CR36","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41419-019-1583-4","volume":"10","author":"Y Huang","year":"2019","unstructured":"Huang Y, Li Q, Zhang K, Hu M, Wang Y, Du L, Lin L, Li S, Sorokin L, Melino G, et al. Single cell transcriptomic analysis of human mesenchymal stem cells reveals limited heterogeneity. Cell Death Dis. 2019;10(5):368.","journal-title":"Cell Death Dis"},{"issue":"4","key":"3941_CR37","doi-asserted-by":"publisher","first-page":"152041","DOI":"10.1016\/j.acthis.2023.152041","volume":"125","author":"J Gopalarethinam","year":"2023","unstructured":"Gopalarethinam J, Nair AP, Iyer M, Vellingiri B, Subramaniam MD. Advantages of mesenchymal stem cell over the other stem cells. Acta Histochem. 2023;125(4):152041.","journal-title":"Acta Histochem"},{"issue":"6","key":"3941_CR38","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41423-023-01022-z","volume":"20","author":"N Kadri","year":"2023","unstructured":"Kadri N, Amu S, Iacobaeus E, Boberg E, Le Blanc K. Current perspectives on mesenchymal stromal cell therapy for graft versus host disease. Cell Mol Immunol. 2023;20(6):613\u201325.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"3941_CR39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13287-024-03707-2","volume":"15","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Huang C, Zheng L, Li Q, Ge J, Geng S, Zhai M, Chen X, Yuan H, Li Y, et al. Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I\/II randomized, double-blind, placebo-controlled study. Stem Cell Res Ther. 2024;15(1):122.","journal-title":"Stem Cell Res Ther"}],"container-title":["Stem Cell Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-024-03941-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-024-03941-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-024-03941-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T20:30:04Z","timestamp":1727469004000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-024-03941-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3941"],"URL":"https:\/\/doi.org\/10.1186\/s13287-024-03941-8","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The retrospective clinical study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Boards of the First Affiliated Hospital of Nanjing Medical University Ethics Committee: (1) No. 2019-MD-512; Title: Safety and efficacy of anti-CD19 CAR-T treatment in DLBCL Subjects; Date of approval: January 15, 2020; (2) No. 2019-SR-335; Title: A study on the efficacy and safety of CD20 CAR-T for the treatment of B-cell lymphoma; Date of approval: August 28, 2019. Written informed consents were obtained from all the patients before enrollment.\u00a0All animal care and experimental procedures were complied with the standards of Animal Welfare for the Care and Use of Laboratory Animals of Nanjing Medical University, and were approved by Institutional Animal Care and Use Committee (IACUC) of Nanjing Medical University (No. 2201014. Title: Effect of mesenchymal stem cells on hematopoietic injury after CAR-T therapy in mice. Date of approval: January 11, 2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors confirm their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests in this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"333"}}